Precision medicine
Focus on analytics, data and maintaining patient access, speakers at the Pop Health Forum in Boston say.
Precision medicine holds the promise of combatting diseases in whole new ways, but the barrier to entry is pretty high.
Lack of sales from its GPC Cancer diagnostic test dragged down finances as the company continues to face public scrutiny.
The multi-year research agreement will see the pharmaceutical company putting Cota's analytics platform to work for improved breast cancer treatment outcomes.
Researchers say the Intermountain Chronic Disease Risk Score can predict which patients will receive a first diagnosis within three years.
Company officials said the competition offers a total of $100,000 for three winners, with first place taking $50,000.
Two Advisory Board research leaders discuss the current state of precision medicine – and what it will take for genomics to become part of routine care.
The lack of adequate EHR interoperability continues to hinder healthcare organizations ability to use patient data in care delivery, the report’s author said.
A single investor is suing the biotech mogul and NantHealth, alleging violation of federal securities laws. Other law firms have also filed class action suits against the company.
The report claims the biotech mogul used charitable donations to benefit his health tech company.